List view / Grid view
Junior Editor of European Pharmaceutical Review, Victoria Rees, speaks with LBC's Tom Swarbrick about the glass vials needed to contain the Oxford-AstraZeneca COVID-19 vaccine.
This on-demand webinar focuses on the importance of cleaning and disinfection, covering legal requirements and the global guidelines for disinfection in cleanrooms.
Total Organic Carbon (TOC) analysis is used to comply with compendia water testing requirements. Read this document to learn the basics on TOC.
Phase III trial data suggests the mRNA-1273 vaccine is safe and highly effective at preventing COVID-19 in adults.
The All India Drug Action Network has said it is "shocked" India has given approval to Covaxin, a COVID-19 vaccine with a lack of peer reviewed safety and efficacy data.
Brian Pinker was the first person to receive AZD1222, the COVID-19 vaccine developed by the University of Oxford and AstraZeneca, this morning.
Europe will receive an extra 80 million doses of Moderna's mRNA-1273, a COVID-19 vaccine candidate, following the EC's decision.
Despite the stringent storage conditions required for Pfizer and BioNTech’s COVID-19 vaccine, the need for a return to normal life has levelled the playing field for all candidate prophylactics against SARS-CoV-2.
Valneva has initiated its Phase I/II trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
As the global COVID-19 response continues, so does the rapidly expanding pipeline for a novel COVID-19 vaccine. Here, experts from Avalere Health outline ongoing US and global vaccine development efforts, including the role of public-private partnerships in accelerating vaccine development. They will also focus on the broader context of respiratory…
Studies show that more than a fifth of the global population, mostly in low- and middle-income countries, may have to wait until at least 2022 to receive a COVID-19 vaccine.
The first participant has been enrolled in a Phase IIb/III study of CVnCoV, CureVac's mRNA COVID-19 vaccine candidate.
Ethicist says that, should trials offer the huge benefits and low risks, he finds no compelling ethical objection to challenge trials for COVID-19 vaccines.
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-300x278.jpg)
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-scaled-e1607955047519.jpg)
The US has approved emergency use of Pfizer and BioNTech’s COVID-19 vaccine, BNT162b2, in people 16 years of age and older.
AstraZeneca will begin testing whether they can improve the efficacy of AZD1222 by combining it with the Ad26 human adenoviral vector from Russia’s Sputnik V vaccine.
